• Je něco špatně v tomto záznamu ?

Integrative Approach to Predict Severity in Nonketotic Hyperglycinemia

OK. Hübschmann, NA. Juliá-Palacios, M. Olivella, P. Guder, DI. Zafeiriou, G. Horvath, J. Kulhánek, TS. Pearson, A. Kuster, E. Cortès-Saladelafont, S. Ibáñez, MC. García-Jiménez, T. Honzík, R. Santer, K. Jeltsch, SF. Garbade, GF. Hoffmann, T....

. 2022 ; 92 (2) : 292-303. [pub] 20220616

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22024960

OBJECTIVE: Glycine encephalopathy, also known as nonketotic hyperglycinemia (NKH), is an inherited neurometabolic disorder with variable clinical course and severity, ranging from infantile epileptic encephalopathy to psychiatric disorders. A precise phenotypic characterization and an evaluation of predictive approaches are needed. METHODS: Longitudinal clinical and biochemical data of 25 individuals with NKH from the patient registry of the International Working Group on Neurotransmitter Related Disorders were studied with in silico analyses, pathogenicity scores, and molecular modeling of GLDC and AMT variants. RESULTS: Symptom onset (p < 0.01) and diagnosis occur earlier in life in severe NKH (p < 0.01). Presenting symptoms affect the age at diagnosis. Psychiatric problems occur predominantly in attenuated NKH. Onset age ≥ 3 months (66% specificity, 100% sensitivity, area under the curve [AUC] = 0.87) and cerebrospinal fluid (CSF)/plasma glycine ratio ≤ 0.09 (57% specificity, 100% sensitivity, AUC = 0.88) are sensitive indicators for attenuated NKH, whereas CSF glycine concentration ≥ 116.5μmol/l (100% specificity, 93% sensitivity, AUC = 0.97) and CSF/plasma glycine ratio ≥ 0.15 (100% specificity, 64% sensitivity, AUC = 0.88) are specific for severe forms. A ratio threshold of 0.128 discriminates the overlapping range. We present 10 new GLDC variants. Two mild variants resulted in attenuated, whereas 2 severe variants or 1 mild and 1 severe variant led to severe phenotype. Based on clinical, biochemical, and genetic parameters, we propose a severity prediction model. INTERPRETATION: This study widens the phenotypic spectrum of attenuated NKH and expands the number of pathogenic variants. The multiparametric approach provides a promising tool to predict disease severity, helping to improve clinical management strategies. ANN NEUROL 2022;92:292-303.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22024960
003      
CZ-PrNML
005      
20240627091433.0
007      
ta
008      
221017s2022 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/ana.26423 $2 doi
035    __
$a (PubMed)35616651
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Hübschmann, Oya Kuseyri $u University Children's Hospital Heidelberg, Division of Child Neurology and Metabolic Disorders, Heidelberg, Germany $1 https://orcid.org/0000000165766566
245    10
$a Integrative Approach to Predict Severity in Nonketotic Hyperglycinemia / $c OK. Hübschmann, NA. Juliá-Palacios, M. Olivella, P. Guder, DI. Zafeiriou, G. Horvath, J. Kulhánek, TS. Pearson, A. Kuster, E. Cortès-Saladelafont, S. Ibáñez, MC. García-Jiménez, T. Honzík, R. Santer, K. Jeltsch, SF. Garbade, GF. Hoffmann, T. Opladen, Á. García-Cazorla
520    9_
$a OBJECTIVE: Glycine encephalopathy, also known as nonketotic hyperglycinemia (NKH), is an inherited neurometabolic disorder with variable clinical course and severity, ranging from infantile epileptic encephalopathy to psychiatric disorders. A precise phenotypic characterization and an evaluation of predictive approaches are needed. METHODS: Longitudinal clinical and biochemical data of 25 individuals with NKH from the patient registry of the International Working Group on Neurotransmitter Related Disorders were studied with in silico analyses, pathogenicity scores, and molecular modeling of GLDC and AMT variants. RESULTS: Symptom onset (p < 0.01) and diagnosis occur earlier in life in severe NKH (p < 0.01). Presenting symptoms affect the age at diagnosis. Psychiatric problems occur predominantly in attenuated NKH. Onset age ≥ 3 months (66% specificity, 100% sensitivity, area under the curve [AUC] = 0.87) and cerebrospinal fluid (CSF)/plasma glycine ratio ≤ 0.09 (57% specificity, 100% sensitivity, AUC = 0.88) are sensitive indicators for attenuated NKH, whereas CSF glycine concentration ≥ 116.5μmol/l (100% specificity, 93% sensitivity, AUC = 0.97) and CSF/plasma glycine ratio ≥ 0.15 (100% specificity, 64% sensitivity, AUC = 0.88) are specific for severe forms. A ratio threshold of 0.128 discriminates the overlapping range. We present 10 new GLDC variants. Two mild variants resulted in attenuated, whereas 2 severe variants or 1 mild and 1 severe variant led to severe phenotype. Based on clinical, biochemical, and genetic parameters, we propose a severity prediction model. INTERPRETATION: This study widens the phenotypic spectrum of attenuated NKH and expands the number of pathogenic variants. The multiparametric approach provides a promising tool to predict disease severity, helping to improve clinical management strategies. ANN NEUROL 2022;92:292-303.
650    _2
$a glycin $x mozkomíšní mok $x genetika $7 D005998
650    _2
$a lidé $7 D006801
650    12
$a neketotická hyperglycinemie $x diagnóza $x genetika $x patologie $7 D020158
650    _2
$a mutace $7 D009154
650    _2
$a fenotyp $7 D010641
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Juliá-Palacios, Natalia Alexandra $u Inborn Errors of Metabolism Unit, Department of Neurology, Recerca Sant Joan de Déu Institute, CIBERER-ISCIII and MetabERN, Barcelona, Spain
700    1_
$a Olivella, Mireia $u Bioinformatics and Medical Statistics Group, Faculty of Science and Technology, Vic University-University of Central Catalonia, Barcelona, Spain
700    1_
$a Guder, Philipp $u Children's Hospital, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
700    1_
$a Zafeiriou, Dimitrios I $u First Department of Pediatrics, Aristotle University of Thessaloniki, Thessaloniki, Greece
700    1_
$a Horvath, Gabriella $u Division of Biochemical Genetics, Department of Pediatrics, University of British Columbia, BC Children's Hospital, Vancouver, British Columbia, Canada
700    1_
$a Kulhánek, Jan $u Department of Pediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic $7 xx0319239
700    1_
$a Pearson, Toni S $u Department of Neurology, Washington University School of Medicine, St Louis, MO, USA $1 https://orcid.org/0000000236797707
700    1_
$a Kuster, Alice $u Department of Neurometabolism and Metabolic Disorders, University Hospital of Nantes, Nantes, France
700    1_
$a Cortès-Saladelafont, Elisenda $u Inborn Errors of Metabolism Unit, Department of Neurology, Recerca Sant Joan de Déu Institute, CIBERER-ISCIII and MetabERN, Barcelona, Spain $u Inborn Errors of Metabolism and Child Neurology Unit, Department of Pediatrics, Germans Trias i Pujol Hospital, Badalona and Faculty of Medicine, Autonomous University of Barcelona, Barcelona, Spain $1 https://orcid.org/0000000286042230
700    1_
$a Ibáñez, Salvador $u Department of Pediatric Neurology, Virgen de la Arrixaca Hospital, Murcia, Spain
700    1_
$a García-Jiménez, Maria Concepción $u Metabolic Diseases Unit, Miguel Servet University Hospital, Zaragoza, Spain
700    1_
$a Honzík, Tomáš $u Department of Pediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
700    1_
$a Santer, René $u Children's Hospital, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
700    1_
$a Jeltsch, Kathrin $u University Children's Hospital Heidelberg, Division of Child Neurology and Metabolic Disorders, Heidelberg, Germany
700    1_
$a Garbade, Sven F $u Dietmar-Hopp Metabolic Center, University Children's Hospital Heidelberg, Heidelberg, Germany
700    1_
$a Hoffmann, Georg F $u University Children's Hospital Heidelberg, Division of Child Neurology and Metabolic Disorders, Heidelberg, Germany
700    1_
$a Opladen, Thomas $u University Children's Hospital Heidelberg, Division of Child Neurology and Metabolic Disorders, Heidelberg, Germany $1 https://orcid.org/0000000343497662
700    1_
$a García-Cazorla, Ángeles $u Inborn Errors of Metabolism Unit, Department of Neurology, Recerca Sant Joan de Déu Institute, CIBERER-ISCIII and MetabERN, Barcelona, Spain
773    0_
$w MED00000428 $t Annals of neurology $x 1531-8249 $g Roč. 92, č. 2 (2022), s. 292-303
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35616651 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20221017 $b ABA008
991    __
$a 20240627091427 $b ABA008
999    __
$a ok $b bmc $g 1854582 $s 1176250
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 92 $c 2 $d 292-303 $e 20220616 $i 1531-8249 $m Annals of neurology $n Ann Neurol $x MED00000428
LZP    __
$a Pubmed-20221017
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace